产品说明书

Cyclophosphamide hydrate

Print
Chemical Structure| 6055-19-2 同义名 : 环磷酰胺水合物;环磷酰胺一水物;环磷酰胺，一水 ;Cyclophosphamide monohydrate;Cyclophosphamide (hydrate);NSC-26271 Monohydrate
CAS号 : 6055-19-2
货号 : A143958
分子式 : C7H17Cl2N2O3P
纯度 : 98%
分子量 : 279.101
MDL号 : MFCD00149395
存储条件：

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 40 mg/mL(143.32 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(179.15 mM)
动物实验配方：
生物活性
描述 Cyclophosphamide triggers outer membrane blebbing, DNA fragmentation (as evidenced by TUNEL staining that highlights free 3'-OH DNA ends), and initiates cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression is capable of completely inhibiting the activation of both initiator and effector caspases, such as caspase 3, in cells treated with activated Cyclophosphamide. However, while Bcl-2 blocks the cytotoxic effects of activated Cyclophosphamide, it does not impede its cytostatic effects[1]. Cyclophosphamide also shows reversible inhibition of AChE with an IC50 value of 511 μM[2].
作用机制 Cyclophosphamide monohydrate attaches the alkyl group to the guanine base of DNA, shown to crosslink with DNA, causing strand breakage and inducing mutations .
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03218852 IgA Nephropathy Phase 4 Active, not recruiting December 2021 China, Guangdong ... 展开 >> Guangdong General Hospital Guangzhou, Guangdong, China, 510080 收起 <<
NCT01670500 Breast Cancer Phase 2 Recruiting October 2021 United States, Colorado ... 展开 >> University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Virginia Borges, MD    303-724-0186    virginia.borges@ucdenver.edu    United States, Connecticut Smilow Cancer Hospital Care Center at Derby Recruiting Derby, Connecticut, United States, 06418 Contact: Erin Hofstatter, MD       erin.hofstatter@yale.edu    Smilow Cancer Hospital Care Center at Guilford Recruiting Guilford, Connecticut, United States, 06437 Contact: Erin Hofstatter, MD       erin.hofstatter@yale.edu    St. Francis Hospital and Medical Center Recruiting Hartford, Connecticut, United States, 06105 Contact: Erin Hofstatter, MD       erin.hofstatter@yale.edu    Yale School of Medicine Recruiting New Haven, Connecticut, United States, 06520 Contact: Erin Hofstatter, MD    203-737-1600    erin.hofstatter@yale.edu    United States, District of Columbia Georgetown University Medical Center Recruiting Washington, District of Columbia, United States, 20007 Contact: Claudine Isaacs, MD       isaacsc@georgetown.edu    Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016-2698 Contact: Antonio Wolff, MD       awolff@jhmi.edu    United States, Maryland Johns Hopkins Recruiting Baltimore, Maryland, United States, 21287 Contact: Antonio Wolff, MD       awolff@jhmi.edu    United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Steven Isakoff, MD, PhD    617-726-4920    sisakoff@partners.org    Principal Investigator: Steven Isakoff, MD, PhD          Dana-Farber Cancer Institute at Faulkner Hospital Withdrawn Boston, Massachusetts, United States, 02130 Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Nadine Tung, MD    617-667-7081    ntung@bidmc.harvard.edu    Principal Investigator: Nadine Tung, MD          Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Judy Garber, MD, MPH    617-632-2282    jegarber@partners.org    Principal Investigator: Judy Garber, MD, MPH          United States, New Hampshire New Hampshire Oncology-Hematology Withdrawn Hooksett, New Hampshire, United States, 03106 United States, New Jersey Rutgers Cancer Institute of New Jersey Active, not recruiting New Brunswick, New Jersey, United States, 08901 United States, New York Memorial Sloan-Kettering Cancer Center Withdrawn New York, New York, United States, 10065 United States, North Carolina Duke University Recruiting Durham, North Carolina, United States, 27708 Contact: P. Kelly Marcom       kelly.marcom@dm.duke.edu    United States, Rhode Island Women and Infants Hospital Recruiting Providence, Rhode Island, United States, 02905 Contact: Robert Legare, MD    401-453-7540    rlegare@wihri.org    United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Banu Arun, MD    713-792-2817    barun@mdanderson.org    MD Anderson in Katy Withdrawn Houston, Texas, United States, 77094 MD Anderson in the Bay Area Withdrawn Nassau Bay, Texas, United States, 77058 MD Anderson - Sugar Land Withdrawn Sugar Land, Texas, United States, 77478 MD Anderson - The Woodlands Withdrawn The Woodlands, Texas, United States, 77384 收起 <<
NCT00296205 Multiple Sclerosis Phase 2 Withdrawn(I am changing locati... 展开 >>ons to Johns Hopkins Medical Center) 收起 << February 2006 United States, New York ... 展开 >> Stony Brook University Hospital Stony Brook, New York, United States, 11794-8174 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.58mL

0.72mL

0.36mL

17.91mL

3.58mL

1.79mL

35.83mL

7.17mL

3.58mL
参考文献

[1]Schwartz PS, et al. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001 Dec;60(6):1268-1279.

[2]Liu P, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010 Jan;33(1):53-9.

[3]Harris RN, et al. Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokineticstudy. Cancer Chemother Pharmacol. 1984;12(3):167-72.